Other Current Assets	9 Months Ended
Sep. 30, 2022
Other Current Assets
Other Current Assets	4. Other Current Assets As of September 30, 2022, other current assets included prepaid expenses of $2.1 million, comprised primarily of prepayments of $1.6 million made for the Company’s clinical trials for BP1002 in separate clinical trials for lymphoma and AML, prexigebersen in AML as well as BP1001-A in solid tumors. Additionally, the Company had prepaid insurance expenses of $0.5 million. As of December 31, 2021, other current assets included prepaid expenses of $1.8 million, comprised primarily of prepayments of $1.4 million made for the Company’s clinical trials for BP1002 in AML and lymphoma, prexigebersen in AML and BP1001-A in solid tumors as well as prepaid insurance of $0.3 million and other prepaid expenses of $0.1 million.

Other Current Assets

9 Months Ended

Sep. 30, 2022

4. Other Current Assets

As of September 30, 2022, other current assets included prepaid expenses of $2.1 million, comprised primarily of prepayments of $1.6 million made for the Company’s clinical trials for BP1002 in separate clinical trials for lymphoma and AML, prexigebersen in AML as well as BP1001-A in solid tumors. Additionally, the Company had prepaid insurance expenses of $0.5 million. As of December 31, 2021, other current assets included prepaid expenses of $1.8 million, comprised primarily of prepayments of $1.4 million made for the Company’s clinical trials for BP1002 in AML and lymphoma, prexigebersen in AML and BP1001-A in solid tumors as well as prepaid insurance of $0.3 million and other prepaid expenses of $0.1 million.